Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
The goal of this study was to compare, with a human tumor xenograft, two different strategies for increasing tumor response to fractionated irradiation, namely, oxygenating the hypoxic tumor cells with carbogen and nicotinamide, or killing these cells with the hypoxic cytotoxin, tirapazamine (TPZ). We used the human hypopharyngeal squamous cell carcinoma cell line FaDu implanted in immune-deficient SCID mice and assessed its response to radiation by cell survival and by growth delay. The tumors were irradiated either once or twice daily with 2 or 2.5 Gy/fraction with either TPZ (0.08 mmol/kg) or nicotinamide (1,000 mg/kg) with carbogen breathing. We also tested the effect of giving TPZ on alternate days, or daily during the first half of the course, the second half, or for the whole course of radiation. We found that adding TPZ or nicotinamide with carbogen to the fractionated radiation regimen enhanced the response of the human xenograft. The enhancement was somewhat greater (though not significantly so) for TPZ, especially when given with each radiation dose. In conclusion, adding TPZ, or nicotinamide plus carbogen, to fractionated irradiation enhanced the response of this human tumor xenograft to fractionated irradiation. Consistent with theoretical modeling, there was a greater enhancement of the radiation response of the tumor when TPZ was given with each radiation dose than when given with only half of the radiation doses.
Department of Radiation Oncology, Stanford University School of Medicine, California 94305-5468, USA.
A
A
el-Said
D
D
Menke
M J
MJ
Dorie
J M
JM
Brown
D000818:Animals; D002245:Carbon Dioxide / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D002470:Cell Survival / Q000528:radiation effects; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D019583:Dose Fractionation, Radiation; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D009536:Niacinamide / Q000008:administration & dosage*; D010100:Oxygen / Q000008:administration & dosage*; D010101:Oxygen Consumption / Q000187:drug effects / Q000528:radiation effects; D010610:Pharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011829:Radiation Dosage; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage*; D012680:Sensitivity and Specificity; D000077704:Tirapazamine; D014227:Triazines / Q000008:administration & dosage*; D014407:Tumor Cells, Cultured / Q000637:transplantation
D011838:Radiation-Sensitizing Agents; D014227:Triazines; D002245:Carbon Dioxide; D000077704:Tirapazamine; D009536:Niacinamide; C011700:carbogen; D010100:Oxygen